CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2014 - 2018)

CytomX Therapeutics' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $1.1 million for Q4 2018.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.1 million (changed N/A YoY) and the FY2018 annual result came in at $1.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability was $1.1 million for Q4 2018 at CytomX Therapeutics, up from $520000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $1.1 million in Q4 2018 and bottomed at $499000.0 in Q4 2014.
• A 5-year average of $570181.8 and a median of $513000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Peak annual rise in Non-Current Deferred Tax Liability reached 5.07% in 2017, while the deepest fall reached 0.78% in 2017.
• CytomX Therapeutics' Non-Current Deferred Tax Liability stood at $499000.0 in 2014, then climbed by 1.6% to $507000.0 in 2015, then increased by 1.18% to $513000.0 in 2016, then gained by 1.36% to $520000.0 in 2017, then jumped by 118.65% to $1.1 million in 2018.
• Business Quant data shows CTMX's Non-Current Deferred Tax Liability at $1.1 million in Q4 2018, $520000.0 in Q3 2017, and $539000.0 in Q2 2017.